Biotech

Latest Articles

Basilea scores $268M BARDA funding for antifungals, prescription antibiotics

.Basilea Pharmaceutica's work building new antifungals has actually acquired a considerable boost fr...

Capricor offers Europe civil rights to late-stage DMD treatment for $35M

.Possessing actually gathered up the U.S. civil rights to Capricor Therapies' late-stage Duchenne mu...

FDA junks adcomm for Applied's unusual ailment drug

.After pushing the decision date for Applied Therapies' metabolic condition medication govorestat, t...

Novo inks $600M NanoVation bargain to examine hereditary medicines ex-liver

.Novo Nordisk is actually proceeding its own push right into genetic medications, agreeing to pay Na...

Innovent links cytokine to colorectal cancer cells responses

.Innovent Biologics has made the case that its gate inhibitor-cytokine blend protein possesses a fut...

Merck, Daiichi ADC reaches objective in phase 3 lung cancer cells research

.A phase 3 trial of Daiichi Sankyo as well as Merck &amp Co.'s HER3-directed antibody-drug conjugate...

Rakovina deepens artificial intelligence focus with collab to decide on cancer cells targets

.Five months after Rakovina Therapeutics pivoted towards expert system, the cancer-focused biotech h...

Ascendis' dwarfism medicine favorites in stage 3, intimidates BioMarin

.Ascendis Pharma has actually become a potential threat to BioMarin's Voxzogo, mentioning period 3 d...

Despite ph. 3 skip, Alkeus observes path in advance for eye illness asset

.Though Alkeus Pharmaceuticals' dental eye health condition possession stopped working to considerab...

Kairos goes social along with $6M IPO to fund trials of cancer cells medication

.With a trio of biotechs striking the Nasdaq on Friday, it was quick and easy to overlook a smaller-...

Vaccine as well as Keytruda combo reliable in squamous cell carcinoma

.Immune checkpoint inhibitors are the superheroes of cancer treatment. Medicines like Bristol Myers ...

Cue Biopharma queues up J&ampJ vet as CBO-- Chutes &amp Ladders

.Accept to recently's Chutes &amp Ladders, our roundup of substantial management hirings, shootings ...

Regeneron's Opdualag opponent reveals 57% reaction rate

.Regeneron is actually back along with long-term follow-up for its own LAG-3 prevention and PD-1 inh...

AstraZeneca blog posts information on internal rivals to AbbVie, Pfizer ADCs

.AstraZeneca has actually shared a very early consider the performance of its own internal antibody-...

iTeos- GSK's TIGIT superstar presents significant enhancement

.After revealing a phase 3 launch based upon beneficial midstage outcomes, iTeos and GSK are ultimat...

More collective FDA may increase uncommon illness R&ampD: file

.The FDA must be actually even more open as well as collective to discharge a surge in approvals of ...

Zenas, MBX, Bicara scalp to Nasdaq in warm time for biotech IPOs

.It is actually an unusually busy Friday for biotech IPOs, along with Zenas BioPharma, MBX and also ...

Atea's COVID antiviral stops working to halt hospitalizations in phase 3

.Atea Pharmaceuticals' antiviral has fallen short another COVID-19 trial, but the biotech still stor...

Neurocrine's offer to save schizophrenia prospect neglects

.Neurocrine Biosciences' mental illness system pivot has failed. The biotech was actually incapable ...

Sanofi pays out $110M upfront for late-stage radioligand treatment

.Sanofi has brought in an overdue entry to the radioligand celebration, paying one hundred thousand ...